Drugs / ISTEM-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03963154 | Aug 2019 → Jun 2023 overdue | retinitis pigmentosa | Centre d'Etude des Cellules Souches | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISTEM-01 | “The primary objective is to assess safety and tolerability of implantation of the Investigational Medecinal Product (ISTEM-01) in patients with retinitis pigmentosa.” NCT03963154 ↗ |
| Modality | Cell therapy | “Human Embryonic Stem Cells-derived Retinal Pigmented Epithelium (hESC-derived RPE)” NCT03963154 ↗ |
| Route | Other | “single central subretinal implantation in one eye” NCT03963154 ↗ |